This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Cevec Pharmaceuticals Gmbh. Active years: 2023-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023-2024
Title: Kerstin Hein: Innovator in AAV Technology
Introduction
Kerstin Hein is a prominent inventor based in Cologne, Germany. She has made significant contributions to the field of biotechnology, particularly in the development of adeno-associated virus (AAV) technologies. With a total of 2 patents, her work has the potential to advance gene therapy applications.
Latest Patents
Kerstin's latest patents focus on inducible AAV Rep genes. The first patent relates to host cells that contain a nucleic acid encoding AAV Rep proteins Rep78 and Rep68. In this invention, the internal AAV promoter p19 has been inactivated through mutations that preserve the functionality of the Rep78 and Rep68 proteins. This innovation also encompasses respective nucleic acids and vectors, along with methods for producing AAV.
Career Highlights
Kerstin Hein is currently associated with Cevec Pharmaceuticals GmbH, where she continues to push the boundaries of AAV research. Her expertise in this area has positioned her as a key player in the biotechnology sector.
Collaborations
Kerstin collaborates with notable colleagues, including Nicole Faust and Silke Wissing. Their combined efforts contribute to the advancement of innovative solutions in the field.
Conclusion
Kerstin Hein's work in AAV technology exemplifies the impact of innovative research in biotechnology. Her patents and collaborations highlight her commitment to advancing gene therapy solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile